Stockscreener 앱 받기
12.00
0.27%
0.0572
Bridgebio Oncology Therapeutics Inc 주식(BBOT)의 최신 뉴스
BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS) - The Manila Times
BridgeBio Oncology Therapeutics, Inc. (BBOT) stock price, news, quote and history - Yahoo! Finance UK
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducin - The Manila Times
Preclinical Data Presented at the 2025 AACR-NCI-EORTC - GlobeNewswire
BBOT presents preclinical data on KRAS inhibitor BBO-11818 - BioWorld MedTech
BridgeBio Oncology announces new preclinical data on BBO-11818 study - TipRanks
BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - The Manila Times
BBOT Presents Preclinical Data Demonstrating Potential of - GlobeNewswire
BridgeBio Oncology (NASDAQ: BBOT) reports BBO-11818 panKRAS data; Phase 1, H2 2026 - Stock Titan
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), OnKure Therapeutics (OKUR) and BridgeBio Oncology Therapeutics (BBOT) - The Globe and Mail
BridgeBio Oncology Therapeutics, Inc. (BBOT) - Yahoo! Finance Canada
BridgeBio affiliate reports 784,720 BBOT shares via services - Stock Titan
Analysts Offer Insights on Healthcare Companies: Bicara Therapeutics Inc. (BCAX) and HUTCHMED (HCM) - The Globe and Mail
BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - The Manila Times
Bbot announces poster presentations at the 2025 AACR-NCI-EORTC International Conference - MarketScreener
Bbot Announces Poster Presentations At The 2025 Aacr-Nci-Eortc International Conference - TradingView
BBOT Announces Poster Presentations at the 2025 - GlobeNewswire
2 Poster Presentations: BBOT to Present KRAS-targeted preclinical data at AACR-NCI-EORTC Oct 2025 - Stock Titan
BridgeBio Oncology Therapeutics, Inc. (BBOT) environment, social and governance (ESG) ratings - Yahoo
BridgeBio Oncology Therapeutics Rings the Closing Bell - Nasdaq
BridgeBio Oncology Therapeutics Inc (NASDAQ: BBOT) Is Up 8.01% – Is It Capable Of A Rally? - stocksregister.com
BridgeBio started at outperform at Leerink on 'differentiated' oncology platform (BBOT:NASDAQ) - Seeking Alpha
Leerink Partners Initiates BridgeBio Oncology Therapeutics at Outperform - MarketScreener
BridgeBio spinout to go public in SPAC deal with Helix Acquisition Corp. II - MSN
H.C. Wainwright initiates BridgeBio Oncology stock with Buy rating - Investing.com India
H.C. Wainwright initiates BridgeBio Oncology stock with Buy rating By Investing.com - Investing.com UK
HC Wainwright Initiates BridgeBio Oncology Therapeutics at Buy With $27 Price Target - MarketScreener
BridgeBio Oncology stock initiated with Outperform rating at Oppenheimer - Investing.com India
BridgeBio Oncology stock initiated with Outperform rating at Oppenheimer By Investing.com - Investing.com Nigeria
Oppenheimer Initiates BridgeBio Oncology Therapeutics at Outperform With $23 Price Target - MarketScreener
After Short Stint as a Private Company, BBOT Leaves SPAC Process Ready To Execute - BioSpace
Helix Acquisition Corp. II Completes Merger with BridgeBio - MSN
BridgeBio Oncology Therapeutics, Inc. (BBOT) company profile and facts - Yahoo! Finance UK
BridgeBio Oncology Therapeutics shares rise 4.57% after-hours after announcing participation in September investor conferences. - AInvest
BBOT to Participate in Upcoming September Investor Healthcare Conferences - The Manila Times
BBOT to Participate in Upcoming September Investor Healthcare Conferences - GlobeNewswire Inc.
BridgeBio's Strategy To Unleash The Full Potential Of RASDrugging The Undruggable - RTTNews
BridgeBio Oncology Therapeutics shares rise 11.34% premarket after Wedbush initiates coverage. - AInvest
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Is In A Good Position To Deliver On Growth Plans - 富途牛牛
We're Hopeful That BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Will Use Its Cash Wisely - Yahoo Finance
We Think BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Can Afford To Drive Business Growth - simplywall.st
BridgeBio Oncology Therapeutics shares rise 1.17% intraday after Piper Sandler initiates coverage. - AInvest
Piper Sandler Initiates BridgeBio Oncology Therapeutics at Overweight With $21 Price Target - MarketScreener
BBOT Forecast — Price Target — Prediction for 2026 - TradingView
BridgeBio Oncology initiated with an Overweight at Piper Sandler - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock Price, News, Quote & History - Yahoo! Finance Canada
What is the current Price Target and Forecast for BridgeBio Oncology Therapeutics, Inc (BBOT) - Zacks Investment Research
Bridgebio Oncology Therapeutics, Inc. shares rise 2.12% intraday after Helix Acquisition Corp. II retains more than 60% of trust account. - AInvest
Cantor Fitzgerald initiates BridgeBio Oncology stock with Overweight rating By Investing.com - Investing.com Australia
Cantor Fitzgerald initiates BridgeBio Oncology stock with Overweight rating - Investing.com
0.21%
0.74%
자본화:
|
볼륨(24시간):